| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Biochemical Oncology, Microbiological Associates, Bethesda, Maryland 20014, [R. E. K., S. A. K., P. J. P.] and Division of Hematology-Oncology, Department of Medicine, Children's Hospital of Los Angeles, and the USC School of Medicine, Los Angeles, California 90027 [W. F. B.]
The potent antileukemic chemotherapeutic drug, 1-ß-D-arabinofuranosylcytosine (ara-C), was observed to transform malignantly secondary hamster fetal cells as well as established rat cells in vitro.
Results indicated that: (a) hamster cells altered by treatment with ara-C are morphologically indistinguishable from cells transformed with benzo(a)pyrene; (b) the ara-C-induced transformation can be observed under conditions of little or no inhibition of DNA synthesis and little or no cytotoxicity; (c) the transformation can occur with only a 6-hr exposure to ara-C; and (d) the transformation of hamster cells seems to require cellular DNA synthesis, for cells in S phase are much more sensitive to ara-C-induced transformation than are G1-arrested cells.
Representative transformed colonies of hamster and rat cells produced rapidly growing fibrosarcomas in inoculated newborn hamsters and rats, respectively. Control cells remained nontumorigenic.
1 Supported in part by contracts from the Council for Tobacco Research, Contract NIH-70-2068 within the Virus Cancer Program, USPHS, and Grant CA 14226 from the NIH.
2 Recipient of a Career Development Award, NIH.
Received 10/29/74. Accepted 5/ 9/75.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |